Can Avigan Bite Into Buzzing Indian Favipiravir Market?

Fujifilm Toyama’s favipiravir may be relatively late on the Indian market,but local partner Dr Reddy’s believes that the large amount of safety data and superior shelf life of the product will hold it in good stead amid heightened competition. Local manufacturing could also help Dr Reddy’s pare the price differential with other versions.

Red umbrella protecting merchants immune novel coronavirus pneumonia infection
Avigan Arrives In India Amid Significant Competition • Source: Shutterstock

Dr. Reddy's Laboratories Ltd. (DRL) has introduced Avigan (favipiravir), licensed from originator Fujifilm Toyama Chemical Co. Ltd., on the Indian market, stepping into a hyper competitive segment that has over half a dozen cut-price generic versions already available.

Dr Reddy’s, while acknowledging it is perhaps a little late on the scene, appears to be banking on the fact...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip